Arcus Biosciences, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $247.0M | $258.0M | $117.0M | $112.0M | $383.0M |
| Operating income | -$386.0M | -$330.0M | -$340.0M | -$280.0M | $54.0M |
| Operating expenses | $633.0M | $588.0M | $457.0M | $392.0M | $329.0M |
| Cash from operations | -$482.0M | -$170.0M | -$306.0M | $438.0M | -$256.0M |
| Capital expenditure | $2.0M | $6.0M | $24.0M | $6.0M | $26.0M |
| Free cash flow | -$484.0M | -$176.0M | -$330.0M | $432.0M | -$282.0M |
| Total assets | $1.1B | $1.1B | $1.1B | $1.3B | $1.6B |
| Total liabilities | — | — | — | — | $750.4M |
| Total debt | $100.0M | $50.0M | $0 | — | — |
Shares outstanding 125.8M · Free float 62.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.